Brief: Panbela Receives Approvals To Open Trial Sites In Spain, France And Italy For Aspire Trial Studying Ivospemin (Sbp-101) In Combination With Gemcitabine And NAB-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
29/09/2022 14:34
Sept 29 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA RECEIVES APPROVALS TO OPEN TRIAL SITES IN SPAIN,
FRANCE
AND ITALY FOR ASPIRE TRIAL STUDYING IVOSPEMIN (SBP-101) IN
COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH
METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
* PANBELA THERAPEUTICS - EXPECT THAT SIGNIFICANT NUMBER OF
GLOBAL
SITES WILL BE OPEN BY YEAR-END WITH FULL COMPLEMENT OF SITES
OPEN BY Q1 2023
Source text for Eikon: ID:nGNX2lbBL8
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants